SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is currently drawing intense investor attention as the company prepares for the upcoming BlueBird 7 satellite launch, with the community actively speculating about potential strategic partnerships and large-scale commercial scaling. Despite some price volatility and debate over short interest, bulls are focused on the company's long-term technical milestones and the build-out of its global satellite constellation.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors weigh aggressive AI infrastructure expansion and a fuel cell partnership against broader software sector weakness. While some in the community see the current price action as a strategic shakeout of weak hands, others remain cautious due to concerns over high debt and shifting sentiment toward AI-driven software.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive parabolic rally fueled by the upcoming addition of the stock to the Nasdaq-100 Index, which has triggered aggressive institutional buying and a short squeeze. Community sentiment is deeply divided, with bulls pointing to long-term AI-driven storage demand and index rebalancing, while vocal bears argue the stock is a bubble driven by retail FOMO and unsustainable valuation.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a flurry of positive catalysts, including a landmark partnership with the University of Cambridge and a new stock registration filing that has kept trading volume high. The community is actively debating the stock's future, balancing enthusiasm for its quantum networking and hardware progress against concerns over dilution and high volatility as the sector experiences significant revaluation.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense trading activity as market speculation intensifies regarding a potential acquisition by Amazon or SpaceX to bolster their satellite internet capabilities. The community is heavily debating the company's valuation, with many long-term shareholders dismissing recent media-reported buyout figures as significant undervaluation of its critical spectrum assets.

Applied Digital Corporation

Applied Digital is drawing significant attention as investors speculate on a looming hyperscaler lease agreement, with community discussions heavily focused on potential catalysts and the critical role of data center infrastructure in the AI sector. While traders debate the significance of specific financing deadlines, bullish sentiment remains tied to the company's long-term expansion potential and its ability to secure high-value partnerships within a booming AI-driven power environment.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened volatility driven by the expansion of its robotaxi partnership with Uber and the announcement of a significant capital raise, even as investors debate the impact of the newly appointed CEO. Community sentiment remains polarized, with many traders focusing on potential dilution and production hurdles while others look toward the company's long-term pivot to a mainstream, higher-volume vehicle platform.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as shareholders react to a bullish letter from CEO Andy Jassy, which revealed significant growth in AWS AI services and custom silicon revenue. The community is actively discussing the company's massive capital expenditure plans and potential for infrastructure dominance, fueling optimistic sentiment around its long-term positioning against other tech heavyweights.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing massive volatility driven by an aggressive short squeeze, with the community intensely debating whether the current rally is a sustainable momentum play or a temporary distortion nearing a 'blow-off top.' Traders are split between those chasing potential further upside and skeptics who are bracing for a sharp correction due to the company's underlying fundamentals and the high cost of borrowing shares.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently surging due to an expanded partnership with Oracle to supply fuel cell capacity for AI-driven data centers, cementing the company's role as a critical power provider in the AI infrastructure boom. The community is actively discussing the stock's parabolic price action and its strategic importance in bypassing grid bottlenecks, with many investors debating the sustainability of its rapid ascent versus potential risks from volatility and market rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis, a rare kidney disorder.</li><li>The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.</li><li>Citi does not see a commercial setback despite a narrower label, according to The Fly.</li></ul>Shares of Travere Therapeutics (TVTX) surged more than 40% in pre-market trading on Tuesday as bullish analyst reactions followed the U.S. Food and Drug Administration (FDA) approval of the company’s Filspari for a rare kidney disorder, making it the first approved treatment for the condition.If the premarket levels hold after the opening bell, <a href="https://stocktwits.com/symbol/TVTX">TVTX shares</a> would surge to their highest since May 2005.<h2 class="st-heading-2">Filspari Becomes The Only Approved FSGS Treatment</h2>On Monday, the U.S. FDA approved Filspari to reduce proteinuria in patients with focal segmental glomerulosclerosis (FSGS). FSGS is a serious condition that causes protein leakage in urine, leading to progressive kidney damage and potential failure. The company estimates that over 30,000 people in the U.S. with FSGS without nephrotic syndrome could be eligible for the treatment.The decision follows a delayed review prompted by the FDA's request for additional data. Approval was supported by late-stage trial results showing Filspari reduced proteinuria by 48% over 108 weeks.Brokerages turned bullish on Travere Therapeutics following the FDA approval. Canaccord raised its price target to $56 from $47 and maintained a ‘Buy’ rating, according to The Fly, projecting peak sales of $547 million for the drug by 2032.Citi analyst Yigal Nochomovitz increased the firm’s price target to $53 from $48, keeping a ‘Buy’ rating. Citi said the approval in FSGS supports the increased target, adding that the narrower label is not seen as a commercial setback. Bank of America also lifted its target to $49 from $44 and reiterated a ‘Buy’ rating on the stock.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours. Messages on the platform increased a whopping 3,200% during the same period, according to Stocktwits data.&nbsp;&nbsp;One user expects “swift uptake for this medicine.”<stembedurl>https://stocktwits.com/pblegend66/message/650201899</stembedurl>Year-to-date, the stock has slid around 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Canaccord projected peak sales of $547 million for the drug by 2032, according to The Fly.

Equity

HC Wainwright Reiterates Buy Rating for Travere Therapeutics (NASDAQ:TVTX)

HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a report on Tuesday...

<ul><li>The agency approved the drug in adult and pediatric patients aged 8 years and older.</li><li>Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome. &nbsp;</li><li>Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy.</li></ul>Travere Therapeutics, Inc. (TVTX) said on Monday that the U.S. Food and Drug Administration has approved its Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis (FSGS), making it the first FDA-approved drug for the indication.The agency approved the drug in adult and pediatric patients aged 8 years and older. Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but without nephrotic syndrome.Filspari was previously greenlit by the FDA for the treatment of IgA nephropathy, a chronic autoimmune kidney disease characterized by the abnormal accumulation of immunoglobulin A (IgA) antibodies in the kidneys' filtering units.<h2 class="st-heading-2">Fresh Approval</h2>While the FDA was previously expected to decide on Travere’s application by January, it pushed it to April after requesting additional information to assess Filspari’s clinical benefit. The company submitted responses, and the agency determined that the responses constitute a major amendment to the application, and extended the review timeline.Filspari was approved in the new indication based on data from a late stage trial where FSGS patients without nephrotic syndrome who were treated with Filspari experienced a 48% reduction in proteinuria from baseline to week 108 compared to 27% for those treated with irbesartan.FSGS is a rare and serious kidney disorder driven by proteinuria or protein leaks into the urine due to a breakdown of the normal filtration mechanism in the kidney. The disease leads to progressive kidney function loss and kidney failure.While TVTX edged 0.2% lower after hours, shares of Ligand Pharmaceuticals (LGND), with which Travere has a licensing agreement for Sparsentan, sold under the Filspari brand, rose 3% at the time of writing.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around TVTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/TVTX">TVTX</a> has gained 107% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/aal-stock-advances-after-hours-following-report-of-ual-ceo-combining-his-past-and-present-companies/cZJ8WmWRIuC">AAL Stock Advances After-Hours Following Report Of UAL CEO Combining His Past And Present Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease

The FDA approved Filspari to reduce proteinuria in some patients with focal segmental glomerulosclerosis.

Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients...

Investors Buy Large Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) was the recipient of unusually large options trading activity on Monday. Investors bought 21,305 call options on the company. This represents an increase of approximately 552% compared to the typical volume of 3,269 call options...

Travere Therapeutics (NASDAQ:TVTX) Trading 7.1% Higher   - Time to Buy?

Travere Therapeutics (NASDAQ:TVTX) Shares Up 7.1% - Should You Buy...

Tudor Investment Corp ET AL Has $2.29 Million Position in Travere Therapeutics, Inc. $TVTX

Tudor Investment Corp ET AL cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 52.5% during the 3rd quarter, according to its most recent 13F filing with the...

Travere Therapeutics (NASDAQ:TVTX)  Shares Down 7.8%   - Should You Sell?

Travere Therapeutics (NASDAQ:TVTX) Shares Down 7.8% - Here's What Happened...

<ul class="summary-bullets"><li>The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.</li><li>Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.</li><li>If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder.</li></ul>Shares of Travere Therapeutics (TVTX) and Ligand Pharmaceuticals (LGND) are drawing increased investor attention ahead of a key U.S. Food and Drug Administration decision on Filspari, a treatment for a rare kidney disease, expected on April 13.Ligand has a licensing agreement with Travere for Sparsentan, sold under the Filspari brand, under which Ligand will receive milestone payments and a 9% royalty on future global net sales of the drug.At the time of writing, <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> and <a href="https://stocktwits.com/symbol/LGND">LGND</a> shares were little changed in pre-market trading on Friday.<h2 class="st-heading-2">FDA Did Not Seek Additional Information On Safety And Manufacturing</h2>In January, Travere Therapeutics announced that the FDA extended the review of its supplemental New Drug Application (sNDA) for Filspari in focal segmental glomerulosclerosis (FSGS), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The FDA did not request any additional information related to the drug’s safety or manufacturing.A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder that can lead to progressive loss of kidney function and eventual kidney failure. Filspari is an oral, non-immunosuppressive therapy.<h2 class="st-heading-2">Citi Expects FDA Approval</h2>Last month, Citi maintained Travere Therapeutics’ ‘Buy’ rating and $48 price target. The firm expects the FDA to approve Filspari and added that the current share price does not fully reflect the company’s opportunity in FSGS.Travere’s Phase 3 study met its interim goal for proteinuria reduction but did not meet the primary kidney function endpoint. However, longer-term results showed the drug improved proteinuria, remission rates, and reduced progression to kidney failure, while remaining well-tolerated. Proteinuria is the high concentration of protein, usually albumin, in urine.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits was ‘bullish’ for TVTX and ‘neutral’ for LGND.One user expects TVTX stock to decline if there is no update before Friday’s close.<stembedurl>https://stocktwits.com/Smellmahass/message/649764886</stembedurl>However, another user expected a pre-FDA run-up to $32 - $35.<stembedurl>https://stocktwits.com/Buckeyeboy722/message/649091978</stembedurl>Year-to-date, TVTX shares have declined 20% while LGND stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake 

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari

Travere Therapeutics (NASDAQ:TVTX) Director Sells $330,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy Baynes sold 10,000 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the director owned...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

Stocktwits

Stocktwits Polls

The stock is surging following FDA approval of Filspari for FSGS, marking it as the first and only medicine available for this rare kidney disease.

Retail investors are betting on a massive short squeeze as over 13 million shares are shorted against a limited retail float following the positive FDA news.

Analysts are aggressively bumping price targets up to $56, citing an estimated addressable market of $3 billion for Filspari across two major rare disease indications.

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TVTX News

TVTXTravere Therapeutics Inc